ArticleCureus2025
Impact of Oral Mesalamine on Clinical Remission and Mucosal Response in Mild to Moderate Ulcerative Colitis: A Prospective Observational Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Ulcerative colitis (UC) is one of the two main types of inflammatory bowel disease (IBD)--the other being Crohn's disease--in which achieving both clinical remission and mucosal healing is essential for optimal long-term outcomes. Objective The objective of this study is to evaluate the impact of oral mesalamine on achieving clinical remission and mucosal healing in patients with mild to moderate UC in a real-world clinical setting. Methodology This prospective observational study was conducted from April 2023 to March 2024 at two tertiary care hospitals in Pakistan: Abbas Institute of Medical Sciences, Muzaffarabad, and HBS Medical and Dental College, Islamabad. A total of 404 adult patients (222 males, 54.95%; 182 females, 45.05%) diagnosed with mild to moderate UC were enrolled. For mild conditions, the doctor recommended 2.4 g of oral mesalamine per day, and for moderate disease, 4.8 g per day. Patients were assessed at 8, 12, and 24 weeks to determine clinical remission, defined as the absence of rectal bleeding and normalization of stool frequency, and mucosal healing, defined as a Mayo endoscopic subscore of 0 or 1. Data were analyzed using SPSS version 25 (IBM Corp., Armonk, NY, US). Chi-square tests and independent t-tests were applied, with a p-value of <0.05 considered statistically significant. Results Of the 404 patients, 367 (90.84%) completed the 24-week follow-up. Clinical remission was achieved in 238 (60.71%) at 8 weeks, 288 (76.39%) at 12 weeks, and 328 (89.37%) at 24 weeks. Mucosal healing was observed in 211 (54.10%) at 8 weeks, 265 (70.29%) at 12 weeks, and 282 (78.12%) at 24 weeks. Among those receiving 2.4 g/day (n=194), 172 (88.66%) achieved remission; in the 4.8 g/day group (n=173), 156 (90.17%) achieved remission. Conclusion Oral mesalamine is highly effective in inducing clinical and mucosal response in mild to moderate UC in routine practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.